PDCD1 and melanoma: With regard to the prognostic impact of PD-1+ TILs, our observations are in line with previous studies showing a positive prognostic effect for PD-1+ TILs in patients with head and neck, ovarian cancer and colorectal cancer, spontaneously-regressing melanoma and folicullar lymphoma [16–19].